University of Ioannina
Το Herceptin (trastuzumab) στη θεραπεία του μεταστατικού καρκίνου του μαστού
Abstract
dc:description100 female patients with metastatic breast cancer were included in this study. Average age was 475 years and they all presented overexpression of the P185 Her-2/neu oncoprotein (c-erb-B2 3+). The patients were divided categorized into two groups. Group A: 50 patients average age 50.5 years. They were treated with Herceptin (Trastuzumab) combined with taxanes (Herceptin/week, taxanes/every 21days/6 cycles). Group B: 50 patients average age 46,,5 years. They were treated with taxanes alone (paclitaxel or docetaxel/week/6 cycles). All of the patients had previously received other chemotherapy regimens. 1) The tumor size was <2 cm in 45% of the patients and >2 and <5 cm in 55% of the patients. 2) The hormone receptors were positive in 52% and negative in 16% of the cases. 3) 98% presented lymphatic metastases, while the percentages of other metastases to other organs were lower regarding patients from group A. Hepatic recurrence frequency was significantly lower in patients treated with the combination Herceptin plus taxanes. 4) Common side effects that have been reported by patients from both groups were: alopecia, nausea, diarrhea, emesis and peripheral oedema. 2% of the patients treated with Herceptin plus taxanes developed cardiotoxicity, which was reversible with the discontinuation of the treatment. 5) The average time-to-progression rate for patients in group A was 8 months, whereas for patients in group B it was 5 months. 6) The overall survival rate for patients in group A, that were treated with Herceptin combined with taxanes was 17 months, whereas for patients in group B it was 7 months. 7) Generally Herceptin is an efficient and safe drug for use as first-line treatment of metastatic breast cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Σιέμπη, Χρυσάνθη
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23362